NCT01863810View on ClinicalTrials.gov

Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain

PHASE3UnknownINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Diabetic Neuropathy
Interventions
DRUG

KW21052

1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.

DRUG

Lyrica

1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.

DRUG

Lyrica (low dose)

1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.

DRUG

Placebo of KW21052

Oral,once a day, for 8 weeks

DRUG

Placebo of Lyrica

Oral, twice a day, for 8 weeks.

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

KunWha Pharmaceutical Co., Ltd.

INDUSTRY